Evercore ISI Group Upgrades Ultragenyx Pharmaceutical to Outperform, Raises Price Target to $80
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Liisa Bayko has upgraded Ultragenyx Pharmaceutical (NASDAQ:RARE) from In-Line to Outperform and raised the price target from $60 to $80.
June 06, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical (NASDAQ:RARE) has been upgraded to Outperform by Evercore ISI Group, with a raised price target of $80.
The upgrade from In-Line to Outperform by Evercore ISI Group analyst Liisa Bayko indicates a positive outlook for Ultragenyx Pharmaceutical. The raised price target from $60 to $80 suggests a potential upside for the stock, which may lead to a short-term increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100